Hormonal therapy of prostatic cancer: current status


Cite item

Full Text

Abstract

References

  1. Oefelein M. G., Feng A., Scolieri M. J. et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56:1021-1024.
  2. Schulman С. С., Irani J., Morote J. et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur. Urol. Suppl. 2010; 9: 675-691.
  3. Morote J., Planas J., Orsola A. et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J. Urol. (Baltimore) 2007; 178: 1290-1295.
  4. Tombal B., Berges R. Optimal control of testosterone: a clinical case-based approach of modem androgen deprivation therapy. Eur. Urol. Suppl. 2008; 7: 15-21.
  5. Tombal В., Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard? Eur. Urol. Suppl. 2005; 4: 30-36.
  6. Berges R. Eligard 6: achieving optimal testosterone control with the convenience of a twice-a-year formulation. Eur. Urol. Suppl. 2007; 6: 840-845.
  7. European Association of Urology guidelines on prostate cancer. 2010.
  8. Wilt T., Nair B., MacDonald R., Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst. Rev. 2009; CD003506.
  9. Loblaw D. A., Virgo K. S., Nam R. et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 2007; 25:1596-1605 .
  10. Medical Research Council Prostate Cancer Working Party Investigators group. Immediate versus deffered treatment for advanced prostatic cancer: initial results of the medical research Council Trial. Br. J. Urol. 1997; 79: 235-246.
  11. Messing E. M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7: 472-479.
  12. Schroder F. H., Kurth K. H., Fossa S. D. Early versus delayed endocrine treatment of T2-T3 pN1-3М0 prostate cancer without local treatment of the primary tumour: final results of European local treatment of cancer protocol 30846 after 13 years of follow-up (a randomized controlled trial). Eur. Urol. 2009; 55: 14-22.
  13. Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002; 360: 103-106.
  14. Pilepich M. V., Winter K., Lawton C. A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61: 1285-1290.
  15. McLeod D. G., Iversen P., See W. A. et al. Bicalutamide 150 mg plus standard care alone for early prostate cancer. Br. J. Urol. Int. 2006; 97: 247-254.
  16. Siddiqui S. A., Boorjian S. A., Inman B. et al. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J. Urol. (Baltimore) 2008; 179: 1830-1837.
  17. Calais da Silva, Bono A. V., Whelan P. et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Urooncological Group. Eur. Urol. 2009; 55: 1269- 1277.
  18. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. Br. J. Urol. Int. 2007; 99 (Suppl. 1): 19-22.
  19. Calais da Silva, Concalves F., Santos A. et al. Evaluation of quality of life, side effects and duration of therapy in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation. Eur. Urol. Suppl. 2008; 7: 205, abstr. 540.
  20. Montorsi F., Berges R., Irani J., Schulman C. Hormone therapy for prostate cancer: exploring current controversies. Eur. Urol. Suppl. 2009; 8:

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies